| Title |
Topiramate for neuropathic pain and fibromyalgia in adults
|
|---|---|
| Published in |
Cochrane database of systematic reviews, August 2013
|
| DOI | 10.1002/14651858.cd008314.pub3 |
| Pubmed ID | |
| Authors |
Philip J Wiffen, Sheena Derry, Michael PT Lunn, R Andrew Moore |
| Abstract |
Topiramate is an antiepileptic drug with multiple possible mechanisms of action. Antiepileptic drugs are widely used to treat chronic neuropathic pain (pain due to nerve damage) and fibromyalgia, and many guidelines recommend them. |
X Demographics
The data shown below were collected from the profiles of 30 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 13 | 43% |
| United Kingdom | 5 | 17% |
| Argentina | 1 | 3% |
| Chile | 1 | 3% |
| Comoros | 1 | 3% |
| Canada | 1 | 3% |
| Unknown | 8 | 27% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 23 | 77% |
| Practitioners (doctors, other healthcare professionals) | 5 | 17% |
| Scientists | 2 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 217 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Spain | 1 | <1% |
| Unknown | 215 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 39 | 18% |
| Student > Bachelor | 31 | 14% |
| Student > Ph. D. Student | 16 | 7% |
| Other | 15 | 7% |
| Student > Doctoral Student | 15 | 7% |
| Other | 38 | 18% |
| Unknown | 63 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 78 | 36% |
| Nursing and Health Professions | 29 | 13% |
| Psychology | 8 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 3% |
| Social Sciences | 6 | 3% |
| Other | 21 | 10% |
| Unknown | 68 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 31. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 July 2023.
All research outputs
#1,293,392
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#2,741
of 11,499 outputs
Outputs of similar age
#11,068
of 212,055 outputs
Outputs of similar age from Cochrane database of systematic reviews
#54
of 231 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,055 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 231 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.